v3.22.4
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2018
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
 [1],[2]
Deferred tax assets:          
Net operating loss carryforwards $ 53.0   $ 46.4 $ 53.0  
Capitalized research and development expenses 49.3   211.9 49.3  
Tax credits 105.5   61.1 105.5  
Share-based compensation 13.3   16.8 13.3  
Fixed and intangible assets 26.4   34.4 26.4  
Accrued liabilities and reserves 105.5   105.3 105.5  
Collaborative agreement milestone accrual 21.9   0.0 21.9  
Convertible debt 21.6   9.3 21.6  
Other 0.5   0.0 0.5  
Total gross deferred tax assets 397.0   485.2 397.0  
Less: valuation allowance (69.9)   (78.7) (69.9)  
Total net deferred tax assets 327.1   406.5 327.1  
Deferred tax liabilities:          
Fixed assets and acquired intangibles assets (42.5)   (69.9) (42.5)  
Other 0.0   (0.3) 0.0  
Total deferred tax liabilities (42.5)   (70.2) (42.5)  
Net deferred tax assets (liabilities) 284.6   336.3 284.6  
Collaborative research and development fee     $ 0.0 $ 87.1 [1],[2] $ 0.0
Collaborative Arrangement, Initial Payment | Verily Life Sciences | Collaborative Arrangement          
Deferred tax liabilities:          
Collaborative research and development fee $ 87.1 $ 217.7      
[1] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.
[2] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.